This is on his Stock Watch list. Balance sheet is pretty dirty with a lot of debt. Company is trying to make major changes, but at this point the risk is far too great for him. Likes the field, which is a growing one.
May have reached its bottom in August. Check the volume from that point. In order to have a bottom, you want 3 X the average volume, a rally and then a correction. If it does not make a new low, that is your signal to buy.
His problem with the stock is that there is only one estimate, so the information given may not be that good. The model price shows as $9.90, a 65% positive differential. Be cautious
Doing very poorly against their US competitor LCA Vision (LCAV-Q). Also had problems with their subsidiary Occulogix when their clinical trial failed. Starting to get beaten up enough to maybe start paying attention to it.
Expensive. Model price is $13.08, so there is a discount and value. Trades at a high multiple to book. If they ever stumble it would sink like a stone.
Also owns a US company LCA Vision (LCAV-Q) and have been selling his TLC shares to buy LCA. Feels LCA is a better run company on the laser vision procedures.
Has been a pretty bumpy ride and still well down from where they were 4/5 years ago. The merger with OccuLogix seems to be a sensible deal. On a 4/5 year basis it is probably going to end up as one of the consolidators. Not sure they will make enough money to make it worthwhile.
Got up to $17 this year and had a correction. Has stayed in the $10/12 area for several months. It is now starting a new upleg. Just went above its 200 day moving average.
Has dropped because there will be a delay in spinning off its Rheopheresis blood filtration process. Interesting speculation. Fundamentals have been improving so it looks good at this price.